Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Pfizer: Significantly More Patients With Cardiovascular Disease Quit Smoking Using Chantix/Champix() (Varenicline) Compared With Placebo
Pfizer: Significantly More Patients With Cardiovascular Disease Quit Smoking Using Chantix/Champix() (Varenicline) Compared With Placebo
Pfizer: Significantly More Patients With Cardiovascular Disease Quit Smoking Using Chantix/Champix() (Varenicline) Compared With Placebo
Submitted by
admin
on March 31, 2009 - 9:07am
Source:
Yahoo
News Tags:
Pfizer
Chantix
Headline:
Pfizer: Significantly More Patients With Cardiovascular Disease Quit Smoking Using Chantix/Champix() (Varenicline) Compared With Placebo
Do Not Allow Advertisers to Use My Personal information
